Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$8.29 USD

8.29
27,781,652

-0.70 (-7.79%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $8.28 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

by Zacks Equity Research

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Zacks Equity Research

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi

by Zacks Equity Research

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

Zacks Equity Research

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Zacks Equity Research

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance

by Zacks Equity Research

Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Stellar Returns

by Tirthankar Chakraborty

Universal Stainless & Alloy Products (USAP), Lakeland Industries (LAKE), NGL Energy Partners (NGL) and Iovance Biotherapeutics (IOVA) have been selected as the breakout stocks for today.

Zacks Equity Research

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

by Zacks Equity Research

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Zacks Equity Research

Company News for Dec 28, 2023

by Zacks Equity Research

Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA

Zacks Equity Research

Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

by Zacks Equity Research

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Zacks Equity Research

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.